Gene therapy edges towards commercial reality
By Reuters,
Reuters
| 05. 25. 2009
LONDON, (Reuters) - Gene therapy may be about to become a commercial reality, 20 years after the first experiments with the ground-breaking medical technology.
But the tale of two biotech companies - one British and one U.S. - suggests a tricky road ahead.
On the one side, French authorities recently allowed an experimental gene medicine from Britain's Ark Therapeutics to be prescribed to certain patients with brain cancer, even though it is not approved for general use.
The news boosted hopes that the European Medicines Agency will clear Ark's drug Cerepro for sale across the European Union in the second half of 2009.
By contrast, U.S.-based Introgen Therapeutics - which had been competing to get the first gene therapy approved in Western markets - filed for bankruptcy in December, after a regulatory setback for its experimental cancer drug Advexin.
The last two decades have seen more than 1,470 clinical trials involving gene therapy, two-thirds of them aimed at cancer, according to the Journal of Gene Medicine.
But the only drug to get to market so far has been one for...
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Yelena Biberman and Jonathan D. Moreno, Bioethics Forum | 04.16.2024
A quiet biological revolution in warfare is underway. The genome is emerging as a new domain of conflict. The level of destruction that only nuclear weapons could previously achieve is fast becoming as accessible as a cyberattack.
Now for the...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...